Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients
Status:
Not yet recruiting
Trial end date:
2028-09-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to compare the efficacy and tolerability of the
combination of two medicinal products, rituximab, and zanubrutinib, compared to rituximab
monotherapy in patients with Splenic Marginal Zone Lymphoma (SMZL), previously untreated and
who need systemic treatment.
The main questions it aims to answer are:
- Is the combination rituximab and zanubrutinib a more effective therapy than rituximab
monotherapy?
- Is the combination therapy, rituximab and zanubrutinib, well tolerated?
Study participants will be put into one of the two treatment groups (rituximab and
zanubrutinib or rituximab alone) for a maximum of two years and will undergo regular visits
until three years from treatment start.
Phase:
Phase 3
Details
Lead Sponsor:
International Extranodal Lymphoma Study Group (IELSG)